Deep Track Capital
VC Fund
Greenwich, United States
Deep Track Capital is an investment firm focused exclusively on the life sciences and biotech industry. It forges partnerships with the management teams of innovative public and pre-IPO biotechnology companies. It seeks to invest its time and expertise, as well as its network, for the benefit of the partners in addition to capital. The firm intendsto lead transactions while forming large syndicates, as well as to participate in rounds led by other qualified investors.
- Total investments:
- 111
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Deep Track Capital invests in
Stages Deep Track Capital invests in
Countries Deep Track Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David E. Kroin
|
|||
Mitchell Kaye
|
|||
Rebecca Luse
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 57 (51%)
- Health Care 30 (27%)
- Therapeutics 25 (23%)
- Medical 18 (16%)
- Pharmaceutical 17 (15%)
Stage
- Post-IPO Equity 30 (27%)
- Series B 18 (16%)
- Series C 9 (8%)
- Series A 3 (3%)
- Series D 2 (2%)
Country
- United States 48 (43%)
- Canada 3 (3%)
- France 3 (3%)
- United Kingdom 3 (3%)
- China 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David E. Kroin
Founder & Chief Investment Officer
|
Founder & Chief Investment Officer | Total investments: 3 | Find email | |
|
Mitchell Kaye
Business Development and Strategy
|
Business Development and Strategy | Total investments: 0 | Find email | |
|
Rebecca Luse
Managing Director
|
Managing Director | Total investments: 13 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LB Pharmaceuticals
|
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $150M / Post-IPO Equity / Jul 29, 2026 | |
Mentari Therapeutics
|
Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M / Private Equity / Jul 22, 2026 | |
Draig Therapeutics
|
Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $65M / Series B / Jul 14, 2026 | |
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
|
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
Triveni Bio
|
Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M / Series C / Jun 17, 2026 | |
cAMPfield Therapeutics
|
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions. | $180M / Series A / May 20, 2026 | |
Valneva
|
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | |
GH Research
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. | $117.5M / Post-IPO Equity / Apr 29, 2026 | |
Maze Therapeutics
|
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $150M / Post-IPO Equity / Apr 22, 2026 | |
| See all 111 investments → | |||
Co-Investors
RA Capital Management
37 deals together
Janus Henderson Investors
23 deals together
Perceptive Advisors
20 deals together
TCG Crossover
20 deals together
Commodore Capital
18 deals together
OrbiMed
18 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Deep Track Capital invest in?
Deep Track Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 111 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Deep Track Capital?
Public channels for Deep Track Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Deep Track Capital?
The team at Deep Track Capital includes David E. Kroin (Founder & Chief Investment Officer), Mitchell Kaye (Business Development and Strategy) and Rebecca Luse (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
